Santen Pharmaceutical Co., Ltd.
Notice of Change in Major Shareholders
As of October 23, 2026, a change in major shareholders was confirmed. Silchester International Investors LLP has become a new major shareholder with a holding ratio of 10.27%. The number of voting rights remained from 33,050,300 shares to 33,050,300 shares, and the post-change voting rights ratio is 10.27%. No specific future outlook was disclosed.
Key Figures
- Major shareholder voting rights ratio: 10.27%
- Number of voting rights after change: 330,503 shares
- Post-change percentage of total shareholders' voting rights: 10.27%
AI要約
Overview
A change in major shareholders was confirmed as of October 23, 2026. Silchester International Investors LLP has strengthened its position as a major shareholder, holding 330,503 shares and representing 10.27% of the total shareholders' voting rights. The change is based on a large-shareholding report submitted on October 26, 2026, and the before-and-after figures were published based on filings submitted to the Financial Services Agency.
Impact and Outlook
While this shareholder change indicates a sizable shift in the market's major shareholder composition, no direct impact on Santen's business plans or shareholder return policy is described. Continued monitoring is required for future movements in shareholder composition and potential effects on capital policy.
Santen Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
